Nanomedicine strategies for acute respiratory distress syndrome management

Acute Respiratory Distress Syndrome (ARDS) remains a critical condition, characterized by severe respiratory failure and high mortality, despite significant advances in understanding its pathophysiology. Current treatments are largely supportive, with no definitive pharmacological solutions available. This review explores the potential of nanomedicine in ARDS management, focusing on nanocarrier-based delivery systems. Lipid nanoparticles (LNPs), particularly for RNA therapeutics, and nanostructured lipid carriers (NLCs) for conventional drug delivery, are highlighted for their enhanced targeting and stability profiles. The clinical success of LNPs in mRNA vaccine delivery demonstrates their efficacy in managing ARDS-related inflammation and tissue damage. Comparative analysis of various nanocarrier platforms reveals distinct advantages, with LNPs offering superior nucleic acid encapsulation efficiency, while NLCs provide enhanced drug-loading capacity and cost-effectiveness. Despite promising preclinical outcomes, clinical translation of nanomedicine in ARDS remains limited, constrained by challenges such as manufacturing scalability, regulatory hurdles, and potential immunogenicity. Moving forward, precision nanotherapies tailored to specific ARDS stages and triggers are essential for improving patient outcomes. This review underscores the need for further research to optimize nanocarrier properties and overcome current limitations, ultimately accelerating the clinical adoption of nanomedicine in ARDS treatment.